OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model
Copyright © 2023 Primard, Monchâtre-Leroy, Del Campo, Valsesia, Nikly, Chevandier, Boué, Servat, Wasniewski, Picard-Meyer, Courant, Collin, Salguero, Le Vert, Guyon-Gellin and Nicolas..
Spike-based COVID-19 vaccines induce potent neutralizing antibodies but their efficacy against SARS-CoV-2 variants decreases. OVX033 is a recombinant protein composed of the full-length nucleocapsid (N) protein of SARS-CoV-2 genetically fused to oligoDOM®, a self-assembling domain which improves antigen immunogenicity. OVX033 including N as an antigenic target is proposed as new vaccine candidate providing broad-spectrum protection against sarbecoviruses. OVX033 demonstrated its ability to trigger cross-reactive T cell responses and cross-protection against three variants of SARS-CoV-2 (B.1 Europe, Delta B.1.617.2, and Omicron B.1.1.529) in a hamster challenge model, as evidenced by lower weight loss, lower lung viral loads, and reduced lung histopathological lesions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Frontiers in immunology - 14(2023) vom: 09., Seite 1188605 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Primard, Charlotte [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 07.07.2023 Date Revised 18.07.2023 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.3389/fimmu.2023.1188605 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359102573 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359102573 | ||
| 003 | DE-627 | ||
| 005 | 20231226210610.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fimmu.2023.1188605 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1196.xml |
| 035 | |a (DE-627)NLM359102573 | ||
| 035 | |a (NLM)37409116 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Primard, Charlotte |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.07.2023 | ||
| 500 | |a Date Revised 18.07.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Primard, Monchâtre-Leroy, Del Campo, Valsesia, Nikly, Chevandier, Boué, Servat, Wasniewski, Picard-Meyer, Courant, Collin, Salguero, Le Vert, Guyon-Gellin and Nicolas. | ||
| 520 | |a Spike-based COVID-19 vaccines induce potent neutralizing antibodies but their efficacy against SARS-CoV-2 variants decreases. OVX033 is a recombinant protein composed of the full-length nucleocapsid (N) protein of SARS-CoV-2 genetically fused to oligoDOM®, a self-assembling domain which improves antigen immunogenicity. OVX033 including N as an antigenic target is proposed as new vaccine candidate providing broad-spectrum protection against sarbecoviruses. OVX033 demonstrated its ability to trigger cross-reactive T cell responses and cross-protection against three variants of SARS-CoV-2 (B.1 Europe, Delta B.1.617.2, and Omicron B.1.1.529) in a hamster challenge model, as evidenced by lower weight loss, lower lung viral loads, and reduced lung histopathological lesions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a T cell immunity | |
| 650 | 4 | |a broad-spectrum protection | |
| 650 | 4 | |a cross-reactive immune responses | |
| 650 | 4 | |a lung histopathology | |
| 650 | 4 | |a lung viral load | |
| 650 | 4 | |a recombinant nucleocapsid | |
| 650 | 4 | |a sarbecovirus vaccine | |
| 650 | 4 | |a universal vaccine | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 700 | 1 | |a Monchâtre-Leroy, Elodie |e verfasserin |4 aut | |
| 700 | 1 | |a Del Campo, Judith |e verfasserin |4 aut | |
| 700 | 1 | |a Valsesia, Séverine |e verfasserin |4 aut | |
| 700 | 1 | |a Nikly, Elsa |e verfasserin |4 aut | |
| 700 | 1 | |a Chevandier, Marion |e verfasserin |4 aut | |
| 700 | 1 | |a Boué, Franck |e verfasserin |4 aut | |
| 700 | 1 | |a Servat, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Wasniewski, Marine |e verfasserin |4 aut | |
| 700 | 1 | |a Picard-Meyer, Evelyne |e verfasserin |4 aut | |
| 700 | 1 | |a Courant, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Collin, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Salguero, Francisco J |e verfasserin |4 aut | |
| 700 | 1 | |a Le Vert, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Guyon-Gellin, Delphine |e verfasserin |4 aut | |
| 700 | 1 | |a Nicolas, Florence |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in immunology |d 2010 |g 14(2023) vom: 09., Seite 1188605 |w (DE-627)NLM215811453 |x 1664-3224 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |g day:09 |g pages:1188605 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fimmu.2023.1188605 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2023 |b 09 |h 1188605 | ||